Physician profile
Ryan M Carr
NPI 1942594932
$267,634.63
in general payments reported to CMS, 2019-2025
57 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $31K · 2021: $27K · 2022: $32K · 2023: $27K · 2024: $33K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Food and Beverage: $11K · Travel and Lodging: $11K · Honoraria: $8,600 · Consulting Fee: $7,015 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,676.50 |
| Food and Beverage | $11,429.66 |
| Travel and Lodging | $11,272.33 |
| Honoraria | $8,600.00 |
| Consulting Fee | $7,015.00 |
| Education | $217.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $76,303.85 | 2019-2025 | |
| Array Biopharma INC | $51,919.28 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $26,310.23 | 2022-2025 | Zepzelca |
| Pfizer INC. | $25,238.31 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $19,483.88 | 2020-2025 | Cosela, Monoferric |
| G1 Therapeutics, INC. | $15,581.31 | 2022-2023 | Cosela |
| Astrazeneca Pharmaceuticals Lp | $12,498.16 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $11,671.85 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Deciphera Pharmaceuticals INC. | $11,242.01 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2022 | |
| Karyopharm Therapeutics INC. | $1,905.00 | 2022 | |
| Beigene USA, INC. | $1,762.04 | 2022-2024 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $1,502.05 | 2019-2025 | Libtayo |
| Adc Therapeutics America, INC. | $1,138.33 | 2021-2025 | |
| Taiho Oncology, INC. | $1,131.36 | 2019-2024 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $1,065.23 | 2019-2020 | |
| Celgene Corporation | $648.75 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $421.76 | 2019-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $404.80 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Adaptive Biotechnologies Corporation | $390.52 | 2022-2025 | Clonoseq |
| Astellas Pharma US INC | $384.69 | 2019-2025 | Padcev, Vyloy |
| Exelixis INC. | $353.50 | 2019-2025 | Cabometyx |
| Eisai INC. | $353.12 | 2019-2025 | |
| Incyte Corporation | $307.88 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Intera Oncology, INC | $303.24 | 2025 | Intera |
| Gilead Sciences, INC. | $295.07 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $270.05 | 2020-2025 | Ojjaara |
| Janssen Biotech, INC. | $261.85 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Genmab U.S., INC. | $238.93 | 2024-2025 | Epkinly |
| Seagen INC. | $220.55 | 2023-2025 | Tukysa |
| Novartis Pharmaceuticals Corporation | $201.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.15 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $186.06 | 2022-2024 | Fotivda |
| Amgen INC. | $179.37 | 2019-2023 | Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $150.62 | 2019-2025 | Iclusig, Fruzaqla |
| Genentech USA, INC. | $138.30 | 2019-2020 | |
| Abbvie INC. | $108.54 | 2019-2025 | Venclexta |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Lilly USA, LLC | $86.61 | 2019-2024 | Verzenio |
| Stryker Corporation | $85.20 | 2024 | Optablate |
| Pharmacyclics LLC, An Abbvie Company | $66.15 | 2019-2023 | Imbruvica |
| Teva Pharmaceuticals USA, INC. | $62.97 | 2019-2020 | |
| Dova Pharmaceuticals | $52.64 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $51.50 | 2019-2020 | |
| Emd Serono, INC. | $51.22 | 2020-2025 | Bavencio |
| Tesaro, INC. | $48.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.58 | 2019 | |
| Myriad Genetic Laboratories, INC. | $46.35 | 2021 | |
| Tersera Therapeutics LLC | $37.35 | 2023 | Zoladex |
| Cycle Pharmaceuticals INC | $21.09 | 2025 | Phyrago |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.41 | 2024 | Gilotrif |
| Stemline Therapeutics INC. | $17.72 | 2024 | Orserdu |
| Fennec Pharmaceuticals, INC. | $15.16 | 2025 | Fyarro |
| Kyowa Kirin, INC. | $14.14 | 2024 | Poteligeo |
| Foundation Medicine, INC. | $11.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.21 | 2019 | |
| Heron Therapeutics, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.